Moderna Q1 2026 Revenue Surges 260%, Legal Costs Weigh on Earnings

Moderna reported its financial results for the first quarter of 2026. The company's revenue increased by 260% compared to the same period last year, driven by strong vaccine sales. However, profitability was pressured by ongoing legal proceedings. Moderna recorded significant legal expenses related to various lawsuits, which negatively impacted net profit margins. Management stated that they are taking strategic steps to improve operational efficiency and manage legal risks. The company also emphasized that new product development efforts continue at full pace. Investors are closely monitoring the impact of the legal burden on the company's financial health despite the strong revenue growth. Moderna's stock experienced volatility following the release of the results. This is not investment advice.

📊 MRNA — Piyasa Yorumu

▲ up · 70%

The news highlights a strong 260% increase in Moderna's revenues, which is a positive fundamental factor for the stock. Technical indicators also support this optimism: the RSI at 63 maintains an upward trend without entering overbought territory, and the MACD is above the signal line and in positive territory. The price is trading above the 20- and 50-day moving averages and has gained 9.3% in the last 24 hours. However, I believe the upside may be limited in the short term due to pressure from legal costs and the risk of overbought conditions.

RSI 14

63.0

MACD

0.54

24h Δ

9.32%

Canlı Grafikler